Valeo Health, a trailblazer in AI-driven personalized healthcare, has successfully closed a $12 million Series B funding round, bringing its total funding to $20 million. The investment will fuel Valeo’s mission to provide science-backed, data-driven healthcare solutions across the Gulf Cooperation Council (GCC) region and beyond.
The round was led by Flintera, with participation from Nuwa Capital, FJ Labs, Oryx, Mindshift Capital, and new investors such as Oraseya and Eirad.
Expanding Personalized Care Across the Region
Valeo Health, founded by Sundeep Sahni, Nadine Karadag, and Ankur Majumder, is renowned for its Longevity technology and personalized healthcare services, including at-home treatment plans powered by AI. The new funding will allow Valeo to extend its footprint in the UAE, Saudi Arabia, and the broader GCC while scaling its AI-powered healthcare solutions.
“We are thrilled by the investor confidence in our mission to transform healthcare engagement,” said Sundeep Sahni, CEO and Co-Founder of Valeo Health. “This investment will help us enhance our technology and product offerings, reaching more individuals with personalized, proactive healthcare solutions.”
Co-founder Nadine Karadag added, “This funding validates our team’s dedication and accelerates our ability to expand personalized care across the region.”
Valeo’s innovations were recently recognized when the company was selected for the Google for Startups Growth Academy: AI for Health, a prestigious program supporting top healthtech innovators. The company’s focus on personalized care, genomics, lifestyle medicine, and AI reflects the growing momentum of these trends in the regional healthcare landscape.
Shaping the Future of Healthtech
Valeo Health’s mission to redefine healthcare through AI-driven insights and customized wellness pathways places it at the forefront of a new era in health and wellness in the GCC region.
